Fidaxomicin(LuciFida)

Fidaxomicin is an antimicrobial drug used to treat associated diarrhea caused by Clostridium difficile (CDAD), with significant therapeutic effect and targeting. It was approved by the FDA for marketing in the United States on May 27, 2011, and should be used only for the treatment of infections that have been proven or strongly suspected to be caused by Clostridium difficile.

Lucius Related Certificates

Drug Testing Report

Drug Marketing Authorization Certificate

Target of Action

Bacterial RNA polymerase

Dosage and Administration

Route and frequency of administration for Fidaxomicin: Oral administration, 200 mg twice daily.

Dosage adjustment of fidaxomicin should be made according to the patient’s actual condition. For specific adjustments, consult a doctor and strictly follow medical advice.

Recommended reading: Dosage and Administration of Fidaxomicin

Side Effects

Common side effects: Nausea, vomiting, abdominal pain, diarrhea, constipation, etc.

Serious side effects: Allergic reactions such as urticaria, rash, pruritus, etc.

Reference article: Side Effects of Fidaxomicin

Use in Special Populations

Pregnancy: Available data are insufficient to assess drug‑associated risks.

Lactation:It is unknown whether fidaxomicin or its metabolites are excreted in human milk.A decision should be made balancing the benefits of breastfeeding and the mother’s clinical need for treatment.

Daily Precautions

Take fidaxomicin exactly as prescribed by your doctor. Follow all directions on the prescription label and read all medication guides or instructions.

This medicine may be taken with or without food.

When measuring a dose for a child, follow instructions carefully. Pediatric dosage of fidaxomicin is calculated based on body weight.

FDA,2020.05